Fidelity Investments
PEAR

Fidelity Investments’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

Fidelity Investments’s Portfolio PEAR Stock Details PEAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-33,192
Closed -$8.46K – 5689
2023
Q1 		$8.46K Buy
33,192
+32,154
+3,098% +$29K ﹤0.01% 4193
2022
Q4 		$1.23K Buy
1,038
+722
+228% +$1.52K ﹤0.01% 4612
2022
Q3 		$1K Buy
+316
New +$536 ﹤0.01% 4783

Fidelity Investments's PEAR Position: Q2 2023 in Review

Fidelity Investments sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q2 2023, closing a stake of 33,192 shares — an estimated $8.46K sold.

Fidelity Investments first reported a position in PEAR in Q3 2022 and held it in 3 quarters. The position peaked at $8.46K in Q1 2023. 1 fund tracked by Wall St. Rank holds PEAR as of Q2 2023.

  • Fidelity Investments reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
  • Fidelity Investments sold 33,192 Pear Therapeutics, Inc. Class A Common Stock shares in Q2 2023, an estimated $8.46K.
  • Fidelity Investments first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q3 2022 and held it in 3 quarters.
  • Fidelity Investments's Pear Therapeutics, Inc. Class A Common Stock position peaked at $8.46K in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q2 2023.

Based on Fidelity Investments's 13F filing for Q2 2023, filed 11 Aug 2023.